102 related articles for article (PubMed ID: 16757353)
1. Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth.
Baines AT; Lim KH; Shields JM; Lambert JM; Counter CM; Der CJ; Cox AD
Methods Enzymol; 2006; 407():556-74. PubMed ID: 16757353
[TBL] [Abstract][Full Text] [Related]
2. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling.
Campbell PM; Groehler AL; Lee KM; Ouellette MM; Khazak V; Der CJ
Cancer Res; 2007 Mar; 67(5):2098-106. PubMed ID: 17332339
[TBL] [Abstract][Full Text] [Related]
3. The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer.
Jin K; Park S; Ewton DZ; Friedman E
Cancer Res; 2007 Aug; 67(15):7247-55. PubMed ID: 17671193
[TBL] [Abstract][Full Text] [Related]
4. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells.
Lim KH; O'Hayer K; Adam SJ; Kendall SD; Campbell PM; Der CJ; Counter CM
Curr Biol; 2006 Dec; 16(24):2385-94. PubMed ID: 17174914
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.
Zhang YA; Nemunaitis J; Samuel SK; Chen P; Shen Y; Tong AW
Cancer Res; 2006 Oct; 66(19):9736-43. PubMed ID: 17018633
[TBL] [Abstract][Full Text] [Related]
6. An anti-K-ras ribozyme suppresses oncogene expression and cell growth of human pancreatic cancer.
Sakuma T; Kijima H; Nishi M; Abe Y; Yamazaki H; Mine T; Nakamura M; Ueyama Y
Tokai J Exp Clin Med; 2004 Jun; 29(2):35-42. PubMed ID: 15473338
[TBL] [Abstract][Full Text] [Related]
7. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
8. The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras.
Tsang WP; Kwok TT
Carcinogenesis; 2009 Jun; 30(6):953-9. PubMed ID: 19372139
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras.
Brunner TB; Cengel KA; Hahn SM; Wu J; Fraker DL; McKenna WG; Bernhard EJ
Cancer Res; 2005 Sep; 65(18):8433-41. PubMed ID: 16166322
[TBL] [Abstract][Full Text] [Related]
10. Harnessing RNAi for analyses of Ras signaling and transformation.
Whitehurst AW; White MA
Methods Enzymol; 2006; 407():259-68. PubMed ID: 16757330
[TBL] [Abstract][Full Text] [Related]
11. The c-K-ras gene and human cancer (review).
Kahn S; Yamamoto F; Almoguera C; Winter E; Forrester K; Jordano J; Perucho M
Anticancer Res; 1987; 7(4A):639-52. PubMed ID: 3310850
[TBL] [Abstract][Full Text] [Related]
12. Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen.
Morgan-Lappe SE; Tucker LA; Huang X; Zhang Q; Sarthy AV; Zakula D; Vernetti L; Schurdak M; Wang J; Fesik SW
Cancer Res; 2007 May; 67(9):4390-8. PubMed ID: 17483353
[TBL] [Abstract][Full Text] [Related]
13. [Study of growth inhibition of lung cancer cells by siRNA targeting mutant K-ras gene in vitro and in vivo].
Zhang ZP; Jiang GC; Yang F; Zhou ZL; Wang J
Zhonghua Wai Ke Za Zhi; 2007 Sep; 45(18):1267-70. PubMed ID: 18067742
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Ras transformation of human thyroid epithelial cells.
Poghosyan Z; Wynford-Thomas D
Methods Enzymol; 2006; 407():648-60. PubMed ID: 16757359
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of retinoblastoma tumor suppressor activity by RNA interference in lung cancer lines.
Reed MF; Zagorski WA; Howington JA; Zilfou JT; Knudsen ES
Ann Thorac Surg; 2006 Jul; 82(1):249-53. PubMed ID: 16798224
[TBL] [Abstract][Full Text] [Related]
16. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
Roberts PJ; Der CJ
Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors induce cell death selectively in cells that harbor activated kRasV12: The role of signal transducers and activators of transcription 1 and p21.
Klampfer L; Huang J; Shirasawa S; Sasazuki T; Augenlicht L
Cancer Res; 2007 Sep; 67(18):8477-85. PubMed ID: 17875686
[TBL] [Abstract][Full Text] [Related]
18. RASSF1A suppresses oncogenic H-Ras-induced c-Jun N-terminal kinase activation.
Yoo YA; Na AR; Lee MS; Yoon S; Kim JS; Yoo YD
Int J Oncol; 2006 Dec; 29(6):1541-7. PubMed ID: 17088994
[TBL] [Abstract][Full Text] [Related]
19. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
[TBL] [Abstract][Full Text] [Related]
20. Ras effector pathways modulate scatter factor-stimulated NF-kappaB signaling and protection against DNA damage.
Fan S; Meng Q; Laterra JJ; Rosen EM
Oncogene; 2007 Jul; 26(33):4774-96. PubMed ID: 17297451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
